实用肝脏病杂志 ›› 2014, Vol. 17 ›› Issue (1): 45-47.doi: 10.3969/j.issn.1672-5069.2014.01.013

• 病毒性肝炎 • 上一篇    下一篇

复方牛胎肝提取物治疗慢性乙型肝炎疗效观察

孙涛, 毛华, 王倩   

  1. 510282广州市 南方医科大学珠江医院消化内科
  • 收稿日期:2013-05-21 出版日期:2014-02-28 发布日期:2016-04-11
  • 通讯作者: 毛华,E-mail:huam@fimmu.com
  • 作者简介:孙涛,女,医学博士,副主任医师。E-mail:gzst2010@126.com

Efficacy of compound embryonic bovine liver extract tablets in treatment of patients with chronic hepatitis B

Sun Tao, Mao Hua, Wang Qian   

  1. Department of Digestive Diseases,Southern Medical University, Guangzhou 510282,China
  • Received:2013-05-21 Online:2014-02-28 Published:2016-04-11

摘要: 目的观察复方牛胎肝提取物片治疗慢性乙型肝炎患者的疗效。方法120例慢性乙型肝炎患者被随机分为治疗组64例和对照组56例。对照组给予基础治疗,治疗组加用复方牛胎肝提取物治疗3 m,观察两组治疗前后临床、肝功能和肝纤维化指标的变化。结果在3 m治疗结束时,治疗组乏力和纳差的改善率分别为92.00%和91.84%,显著高于对照组(56.41%和58.33%,P<0.05);治疗组ALT为(35.6±17.2)U/L、AST为(38.5±18.6)U/L、GGT为(40.6±19.7)U/L、总胆红素为(16.1±13.9)μmol/L,均较治疗前[分别为(110.8±61.4)U/L、(97.2±62.4)U/L、(106.3±60.1)U/L、(47.8±19.3)μmol/L)]显著下降(P<0.05);治疗组基线时III型前胶原肽为(36.7±11.3)μg/L、透明质酸为(276.4±79.5)μg/L、层粘连蛋白为(169.8±73.4)μg/L、IV型胶原为(155.8±61.5)μg/L,治疗后均显著下降[分别为(16.4±6.1)μg/L、(110.8±51.4)μg/L、(70.8±34.9)μg/L、(97.8±41.4)μg/L,P<0.05)]。结论复方牛胎肝提取物片治疗慢性乙型肝炎患者有一定的效果。

关键词: 慢性乙型肝炎, 复方牛胎肝提取物片, 疗效

Abstract: Objective To observe the efficacy of compound embryonic bovine liver extract tablets in treatment of patients with chronic hepatitis B(CHB). Methods One hundred and twenty patients with CHB were recruited, and divided randomly into control group(n=56)or treatment group (n=64);Patients in control group were treated with basic liver-protecting treatment and patients in treatment group were treated with combinational therapy of compound embryonic bovine liver extract tablets and basic treatment. Changes in liver function tests and fibrotic parameters were examed after 3 months of treatment. Results At the end of 3 months of treatment,the fatigue and poor appetite were improved in 92.00% and 91.84%,respectively,in treatment group,significantly higher than those in controls(56.41% and 58.33%,respectively,P<0.05);the serum ALT, AST, GGT and total bilirubin levels in treatment group were (35.6±17.2) U/L,(38.5±18.6) U/L,(40.6±19.7) U/L and (16.1±13.9) μmol/L,respectively,significantly decreased than those before treatment [(110.8±61.4) U/L for ALT,(97.2±62.4) U/L for AST,(106.3±60.1) U/L for GGT and(47.8±19.3) μmol/L for total bilirubin,P<0.05];serum PIIIP(36.7±11.3 μg/L), HA (276.4±79.5 μg/L),LN(169.8±73.4 μg/L) and IV-C (155.8±61.5 μg/L) in treatment group decreased significantly than those before treatment[(16.4±6.1) μg/L for PIIIP,(110.8±51.4) μg/L for HA,(70.8±34.9) μg/L for LN and(97.8±41.4) μg/L for IV-C,P<0.05],which lowered more obviously than in control. Conclusion Compound embryonic bovine liver extract may be a promising therapeutic remedy for patients with CHB.

Key words: Chronic hepatitis B, Compound embryonic bovine liver extract tablets, Therapy